EP1569598A1 - Creme moussante stable - Google Patents

Creme moussante stable

Info

Publication number
EP1569598A1
EP1569598A1 EP03789251A EP03789251A EP1569598A1 EP 1569598 A1 EP1569598 A1 EP 1569598A1 EP 03789251 A EP03789251 A EP 03789251A EP 03789251 A EP03789251 A EP 03789251A EP 1569598 A1 EP1569598 A1 EP 1569598A1
Authority
EP
European Patent Office
Prior art keywords
weight
foam cream
cream
foam
heat treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03789251A
Other languages
German (de)
English (en)
Inventor
Fritz Neubourg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neubourg Skin Care GmbH and Co KG
Original Assignee
Neubourg Skin Care GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neubourg Skin Care GmbH and Co KG filed Critical Neubourg Skin Care GmbH and Co KG
Priority to EP03789251A priority Critical patent/EP1569598A1/fr
Publication of EP1569598A1 publication Critical patent/EP1569598A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the invention relates to a stable foam cream containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to a heat treatment after addition of the propellant gas, and a method for producing a stable foam cream.
  • foam preparations are used, inter alia, as skin creams.
  • the foam is created by foaming a basic preparation with propellant gas. Applying such foam preparations to the treated skin creates a two-dimensional two-phase network, the hydrophilic components bind to the keratin in the horny layer and allow perspiration to evaporate, while the lipophilic components on the skin surface inhibit the penetration of moisture.
  • foam creams are described, inter alia, in laid-open publications WO-A-99/08649 and WO-A-98/31339.
  • foams as aerosols are complex, physicochemical structures that cannot be produced arbitrarily.
  • the stability of such structures depends very much on the special coordination of the components forming the foam. Even slight changes in the composition can cause the foam to collapse. "Collapse” means that the foam immediately after it is released from the can has a lot of bubbles and collapses.
  • the positive properties of the foam (especially its rapid absorption after application to the skin) are thwarted and are not accepted by the users. Therefore, a mixture of substances that are effective per se cannot be easily formulated as foam. It appears
  • WO 99/08649 discloses a technique in which two separate phases I and II are provided, pretreated and mixed according to a precise protocol. The process involves numerous steps that must be carefully checked by the manufacturer.
  • GB-A-2 204 875 relates to a process for the realization of monocarboxylic acids. Finely divided particles with C10-C22 carboxylic acids in an aqueous medium with a neutralizing reagent, e.g. B. ethanolamine contacted at a temperature below the melting point of said fatty acids. This creates pumpable liquid soap solutions containing 0.3% to 40% by weight of soap. Shaving foams are made from this by adding C3 or C4 hydrocarbon propellants.
  • a neutralizing reagent e.g. B. ethanolamine
  • FR-A-2.217.405 relates to the production of foam creams as oil-in-water emulsions.
  • WO-A-98/31339 relates to skin care products from a two-phase system which is able to produce a semipermeable membrane on the skin.
  • the object of the invention is to provide foams which do not essentially collapse and in which the problems described above do not occur. Methods are also to be provided to produce such foams and to make collapsed foams usable again.
  • the problem on which the invention is based is surprisingly solved by a stable foam cream containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to a heat treatment, characterized in that the heat treatment over a period of at least 5, in particular 10 minutes is carried out, and / or for 5 minutes to 2 hours at 40 to 75 ° C.
  • the heat treatment takes place after the addition of the propellant gas.
  • the heat treatment is carried out by heating the propellant gas before and / or when it is added to the cream preparation. Both methods can also be combined according to the invention.
  • the heat treatment after adding the propellant gas must be carried out depending on the time and temperature. There is generally a reciprocal relationship between the temperature of the heat treatment and the duration of the process. If the heat treatment is carried out at a relatively high temperature, a relatively short treatment time is sufficient and vice versa.
  • the heat treatment should in particular be carried out for at least 10 minutes, 30 minutes or 1 hour.
  • the temperature is at least 30 ° C, at least 40 ° C or at least 50 ° C.
  • the temperature should not fall below 20 ° C to avoid too long times.
  • Heat treatments can be carried out at 40 to 70 ° C., in particular 45 to 65 ° C. for 5 minutes to 2 hours, at 40 to 60 ° C. for 10 minutes to 5 hours, or at 30 to 50 ° C. for 20 minutes to 20 hours, in particular 1 h to 15 h.
  • An industrially sensible heat treatment can be carried out, for example, for a period of 20 minutes at 50 ° C, 10 hours at 40 ° C or 12 hours at 38 ° C.
  • heat treatment should take into account the fact that, depending on the propellant gas used, there is a maximum heating limit that should not be exceeded for safety reasons.
  • the heat treatment should be permanent (in the hour range) at no more than about 50 ° C.
  • the heat treatment is preferably carried out by incubation, for example in a heating cabinet, a heating chamber or an incubation room.
  • the heat treatment takes place in particular after the addition of the propellant gas.
  • the cans containing the foam cream can be heat-treated on pallets in heat chambers. Temperatures of 35 - 40 ° C for a period of 10 to 14 hours can be maintained.
  • the foam cream can first be dosed or filled and then exposed to the heat treatment.
  • Another way of producing a stable foam cream is to heat the propellant gas before or during its addition to the hydrophilic and lipophilic components. This is in contrast to known methods in which the propellant gas is supplied with cooling.
  • the propellant gas is preferably heated at 25 to 60 ° C., in particular 25 to 50 ° C. or 25 to 40 ° C. It may be advantageous to heat the propellant to at least 30 ° C or 40 ° C.
  • a leak test of the filled and charged with propellant cans can also be used as heat (partial) treatment in the sense of the present invention.
  • the cans are passed through a water bath heated to 40 - 50 ° C.
  • the corresponding dwell times in the water bath can be counted towards the incubation period.
  • the stable foam cream according to the invention is preferably a two-phase system.
  • the lipophilic components consist of fatty acids and dimethylpolysiloxanes, and the hydrophilic components are selected from the group consisting of triethanolamine, monopropylene glycol, glycerol, sorbitol, polyethylene glycol and polyvinylpyrrolidone.
  • the foam cream according to the invention contains C ⁇ o to C 22 fatty acids, emulsifiers and co-emulsifiers. In a particular embodiment, the foam cream according to the invention contains
  • moisturizer 0.4 to 2.3% by weight moisturizer
  • the foam cream according to the invention can additionally 1 to 3 wt .-% glyceryl stearate,
  • the stable foam cream can additionally contain hydrating (moisture-binding) substances, such as urea, ethoxydiglycol, sodium chloride, magnesium chloride, sorbitol, dexpanthenol, sodium lactate, as further constituents.
  • hydrating moisture-binding substances, such as urea, ethoxydiglycol, sodium chloride, magnesium chloride, sorbitol, dexpanthenol, sodium lactate, as further constituents.
  • the stable foam cream according to the invention has improved properties compared to foam creams known from the prior art.
  • the described phenomenon of collapsing or collapsing of the foams essentially no longer occurs. Rather, the foam creams are stable over a long period of time and are essentially resistant to external disturbing influences, such as shaking during transport or temperature fluctuations.
  • the foam cream according to the invention is also stable if it contains substances which destabilize foam creams not treated according to the invention.
  • the stable foam cream according to the invention is a cosmetic or medical foam cream, in particular a skin foam cream.
  • a cosmetic or medical foam cream in particular a skin foam cream.
  • Common ingredients and additives of such skin creams may be included, such as those disclosed in WO-A-98/31339 or WO-A-99/08649.
  • the invention also relates to a method for producing a stable foam cream containing lipophilic and hydrophilic components and a propellant gas, which is characterized in that in the method a cream preparation containing lipophilic and hydrophilic components is produced, after which propellant gas is added so that a Foam cream is formed and the foam cream is subjected to a heat treatment and / or the propellant gas is heated before and / or during the addition to the cream preparation.
  • the propellant gas is heated before and / or during the addition to the cream preparation.
  • the foam cream has collapsed or partially collapsed after the propellant gas has been added and before the heat treatment has been carried out. This means that the method according to the invention not only makes it possible to stabilize foam creams, but also to restore foam creams that have already broken down after the addition of the propellant gas and can usually no longer be used by the manufacturer by carrying out a heat treatment.
  • Example 1 Preparation of a foam cream
  • the foam cream is produced in a heatable and coolable closed apparatus with a self-discharging homogenizer and a heatable dosing funnel.
  • Phase I is produced in a heated metering funnel by melting a mixture comprising 2% by weight glyceryl stearate, 4% by weight cetearyl alcohol, 5% by weight stearic acid, 1% by weight paraffin, 0.5% by weight.
  • This phase is metered in with stirring to a phase II which is placed in the heatable and coolable closed apparatus with a self-discharging homogenizer.
  • This phase consists of an aqueous mixture containing 5.5% by weight urea, 2.5% by weight. % Propylene glycol, 2.5% by weight glycerin, 2% by weight sodium lauroyl sarcosinate and 63% by weight water.
  • a homogeneous mixture of the two phases I and II must be set.
  • phase I takes place at a temperature of 75 ° C. Both phases are brought together under constant medium stirring speed, whereby uniform homogenization activity must be ensured.
  • the temperature is between 20 and 30 min. at Kept at 75 ° C.
  • 0.1% by weight of allantoin and 1.1% by weight of triethanolamine are added.
  • the mixture obtained is cooled to a temperature between 30 and 40 ° C. with constant stirring.
  • the mixture is stirred for a sufficiently long time until the pH stabilizes and then the filling is filled into suitable storage containers or into the corresponding spray containers with 9% isobutane / butane / propane.
  • a heat treatment is carried out by storing the filled containers in a storage room at 38 ° C. for 12 hours.
  • a viscose cream is prepared by the process according to Example 1.
  • the propane / butane mixture can be warmed to 25 ° C. before addition.
  • a foam cream is produced by the process described in Example 1. After filling the foam cream, the filled containers are heated in a heating cabinet with an internal temperature of 50 ° C. for 20 minutes.
  • a foam cream is produced by the process described in Example 1, in which the propane / butane mixture to be supplied can be heated to 25 ° C. and the filled containers are stored in a storage room at 38 ° C. for 12 hours after the foam cream has been filled.
  • Example 6
  • a foam cream is produced according to Example 1, with the difference that clotrimazole is added to the mixture instead of aloe vera and panthenol and the procedure is continued as described for Example 1.
  • the addition of this component destabilizes foam creams to a high degree and usually leads to the foam cream collapsing.
  • Part of the foam cream is subjected to a heat treatment according to Example 2, another part to a heat treatment according to Example 4.
  • Example 6 The procedure is as described for Example 6, with the difference that oak bark extract is added to the foam cream instead of clotrimazole.
  • the addition of this component can destabilize foam creams and usually causes the foam cream to collapse
  • Example 6 The procedure is as described for Example 6, with the difference that sage is added to the foam cream instead of clotrimazole.
  • the addition of this component destabilizes foam creams to a high degree and usually leads to the foam cream collapsing.
  • Example 6 The procedure is as described for Example 6, with the difference that rosemary is added to the foam cream instead of clotrimazole.
  • the addition of this component destabilizes foam creams to a high degree and usually leads to the foam cream collapsing.
  • Example 11 The procedure is as described for Example 6, with the difference that arnica is added to the foam cream instead of clotrimazole. The addition of this component destabilizes foam creams to a high degree and usually leads to the foam cream collapsing.
  • Example 11 The procedure is as described for Example 6, with the difference that arnica is added to the foam cream instead of clotrimazole. The addition of this component destabilizes foam creams to a high degree and usually leads to the foam cream collapsing.
  • the foam creams according to Examples 2 to 11, which have been subjected to a heat treatment, are stable. A collapse of the creams is not observed. In contrast, the foam creams according to Example 1 tend to collapse without heat treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Grain Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une crème moussante stable contenant des composantes lipophiles et hydrophiles et un gaz propulseur, pouvant être obtenue grâce à un traitement thermique de la crème moussante. L'invention a également pour objet un procédé pour produire ladite crème moussante.
EP03789251A 2002-12-12 2003-12-12 Creme moussante stable Withdrawn EP1569598A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03789251A EP1569598A1 (fr) 2002-12-12 2003-12-12 Creme moussante stable

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43263202P 2002-12-12 2002-12-12
US432632P 2002-12-12
EP02027828 2002-12-12
EP02027828 2002-12-12
PCT/EP2003/014153 WO2004052317A1 (fr) 2002-12-12 2003-12-12 Creme moussante stable
EP03789251A EP1569598A1 (fr) 2002-12-12 2003-12-12 Creme moussante stable

Publications (1)

Publication Number Publication Date
EP1569598A1 true EP1569598A1 (fr) 2005-09-07

Family

ID=35912802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03789251A Withdrawn EP1569598A1 (fr) 2002-12-12 2003-12-12 Creme moussante stable

Country Status (7)

Country Link
US (1) US20070134167A2 (fr)
EP (1) EP1569598A1 (fr)
JP (1) JP2006510651A (fr)
CN (1) CN1723009A (fr)
AU (1) AU2003293865A1 (fr)
EA (1) EA009660B1 (fr)
WO (1) WO2004052317A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
EP1649846A1 (fr) * 2004-10-21 2006-04-26 Neubourg Skin Care GmbH & Co. KG Utilisation d'urée pour le traitement de taches brunes
DE202006004676U1 (de) * 2005-09-28 2007-02-08 Neubourg Skin Care Gmbh & Co. Kg Hautpflegeprodukte
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP2145012A2 (fr) * 2007-04-04 2010-01-20 F. Hoffmann-Roche AG Réduction microbienne d'un acétoxycétone
US20090036856A1 (en) * 2007-07-31 2009-02-05 Kimberly-Clark Worldwide, Inc. Triggerable self-generating liquid foam barrier/interceptor
DE102007036187A1 (de) * 2007-08-02 2008-06-19 Clariant International Limited Alkoxylierte Phosphorsäuretriester mit hohem Alkoxylierungsgrad
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
WO2010041141A2 (fr) 2008-10-07 2010-04-15 Foamix Ltd. Support expansible à base d’huile et préparations
WO2009072007A2 (fr) 2007-12-07 2009-06-11 Foamix Ltd. Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
WO2009090558A2 (fr) 2008-01-14 2009-07-23 Foamix Ltd. Compositions pharmaceutiques pouvant mousser de poloxamère avec des agents actifs et/ou des cellules thérapeutiques, et utilisations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
CA2769625C (fr) 2009-07-29 2017-04-11 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
WO2011013008A2 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes à base d'agents non tensioactifs non polymères, mousses légères, et leurs utilisations
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
CN103596546B (zh) * 2011-05-12 2016-10-26 荷兰联合利华有限公司 皮肤提亮组合物
DE102015221568A1 (de) * 2015-11-04 2017-05-04 Beiersdorf Ag Kosmetischer Schaum aus einer Emulsion enthaltend Glycerin und Alkohol
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970584A (en) * 1973-02-14 1976-07-20 S. C. Johnson & Son, Inc. Aerosol package containing a foam-forming emulsion and propellent system
US4753747A (en) * 1987-05-12 1988-06-28 Colgate-Palmolive Co. Process of neutralizing mono-carboxylic acid
SE520811C2 (sv) * 1997-01-17 2003-08-26 Ponsus Ab Hudskyddspreparat innehållande lipofila och hydrofila komponenter, förfarande för framställning och användning därav
US6423323B2 (en) * 1997-08-18 2002-07-23 Stephanie Neubourg Foam skin cream, uses of the foam skin protection cream and a process for its preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004052317A1 *

Also Published As

Publication number Publication date
US20060099151A1 (en) 2006-05-11
US20070134167A2 (en) 2007-06-14
AU2003293865A1 (en) 2004-06-30
JP2006510651A (ja) 2006-03-30
WO2004052317A1 (fr) 2004-06-24
CN1723009A (zh) 2006-01-18
US20060239937A2 (en) 2006-10-26
EA009660B1 (ru) 2008-02-28
EA200500920A1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
EP1569598A1 (fr) Creme moussante stable
DE3885049T2 (de) Zubereitung zur Hautpflege.
DE69020211T2 (de) Kosmetische Doppelemulsionszusammensetzung.
DE69112601T2 (de) Emulsionszusammensetzung.
DE68926818T2 (de) Selbstschäumende ölzusammensetzungen, verfahren zur herstellung und deren verwendung
DE3445749C2 (de) Beständige gelförmige Rasiercreme
DE69020900T2 (de) Schaumaerosolzusammensetzung.
DE3222471C2 (fr)
DE2406109C2 (de) Treibmittelsystem und dieses enthaltende Aerosolpackung
DE3586436T4 (de) Kosmetische Emulsion und Verfahren zu deren Herstellung.
DE202006014258U1 (de) Schaumhautpflegecreme für Diabetiker
DE2703373C2 (de) Mittel zur Hautbehandlung und Verfahren zu seiner Herstellung
DE1667237A1 (de) Unter Druck stehendes Praeparat und dessen Herstellung
DE3628531A1 (de) Verschaeumbare cremes
EP1014916A2 (fr) Creme moussante de soins corporels, utilisations et procede de production de cette creme
CH678811A5 (fr)
CH634480A5 (de) Unter druck stehendes aerosolpraeparat.
EP1197201A2 (fr) Produit de coiffure à base de cire avec des huiles non volatils et des substances hydrophobes volatiles
DE2216020A1 (de) Kosmetikum mit Reinigungs- und tonischer Wirkung
US3285818A (en) Hair and skin compositions containing pantethine
WO2023280485A1 (fr) Produit de soin capillaire à transformation
DE69821010T2 (de) Aerosol-salben-zubereitungen
US5000938A (en) Protective aerated foam hand lotion and process for preparing the same
DE1667237C3 (de) Unter Druck stehendes Aerosolpräparat und Verfahren zu dessen Herstellung
WO2024017699A2 (fr) Procédé de préparation d'une émulsion cosmétique eau dans huile à partir d'une émulsion glycérine dans huile

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1082406

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUBOURG SKIN CARE GMBH & CO. KG

17Q First examination report despatched

Effective date: 20061115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080811

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1082406

Country of ref document: HK